TICKERNERD
Menu
TECXTECXHealthcare · Biotechnology

TECX Stock Forecast: Tectonic Therapeutic, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$35

The 10 Wall Street analysts covering Tectonic Therapeutic, Inc. hold a median 12-month price target of $80 — +129.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$682.5M
Ticker Nerd rank
52 / 100
Median analyst target
$80
Analysts covering
10
Ticker Nerd rank

TECX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tectonic Therapeutic, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
52 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
78
Accruals
71
Revisions
63
Momentum
63
Value
56
Size
51
Quality
50
Growth
26
Issuance
24

Volatility (78): The share price has been relatively steady.

Issuance (24): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TECX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TECX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says10 analysts
10 Buy0 Hold0 Sell
Low $60Median $80High $93

The green dot is the last close — the median target sits +129.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Aug 2026Wells FargoMaintainsOverweight$101 → $93
26 May 2026Raymond JamesUpgradeStrong Buy$76 → $81
26 May 2026Raymond JamesUpgradeStrong Buy—
14 Apr 2026StifelInitiatesBuy—
8 Jan 2026Truist SecuritiesMaintainsBuy—
3 Sept 2025OppenheimerInitiatesOutperform—
21 July 2025Truist SecuritiesInitiatesBuy—
11 June 2025Raymond JamesReinstatesOutperform$76
6 June 2025LifeSci CapitalInitiatesOutperform—
15 May 2025MizuhoMaintainsOutperform—
21 Apr 2025MizuhoInitiatesOutperform—
21 Mar 2025Wells FargoMaintainsOverweight—
31 Jan 2025Wells FargoMaintainsOverweight—
20 Nov 2024Raymond JamesInitiatesOutperform—
12 Nov 2024Wells FargoMaintainsOverweight—
11 Nov 2024Leerink PartnersMaintainsOutperform—
22 Aug 2024Wells FargoInitiatesOverweight—
24 July 2024Leerink PartnersInitiatesOutperform—
26 June 2024Piper SandlerInitiatesOverweight—
24 June 2024TD CowenInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TECX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

TECX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
7
Fundamentals

Tectonic Therapeutic, Inc. (TECX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
4.6×

Cheaper than 67% of US stocks

Price / sales
—
Price / book
2.9×

Cheaper than 36% of US stocks

EV / EBITDA
−4.9×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−33.8%

Higher than 26% of US stocks

Return on assets
−22.3%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TECX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TECXTectonic Therapeutic, Inc.$682.5M
52
ASMBAssembly Biosciences, Inc.$653.0M
86
SGMTSagimet Biosciences, Inc.$645.5M
30
ZVRAZevra Therapeutics, Inc.$664.6M
97
MDXGMiMedx Group, Inc.$634.4M
74
CBIOCrescent Biopharma, Inc.$633.5M
55
ALLOAllogene Therapeutics, Inc.$679.1M
79

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tectonic Therapeutic, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TECX news & analysis

Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewsWire · 6 Aug 2026positive

Tectonic Therapeutic reported second-quarter 2026 financial results and business highlights, including completion of enrollment in the TX45 APEX Phase 2 trial in PH-HFpEF with topline results expected in early Q1 2027, an IDMC recommendation to continue that study without modification, and completion of dosing for six healthy volunteer cohorts in the TX2100 Phase 1a trial with topline results anticipated by end of Q3 2026. The company reported cash and equivalents of $227.1 million as of June 30, 2026, expected to fund operations into Q1 2029.

Why it matters — A TECX watcher would care because the update signals steady clinical progress across the TX45 and TX2100 programs and confirms the company has sufficient cash runway into Q1 2029.

FAQ

Frequently asked questions about TECX stock

What is the TECX stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Tectonic Therapeutic, Inc. have a median 12-month price target of $80, with estimates ranging from $60 to $93. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TECX stock a buy right now?

Of the 10 analysts covering Tectonic Therapeutic, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tectonic Therapeutic, Inc. 52 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TECX?

As at 15 Aug 2026, Tectonic Therapeutic, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (78 of 100).

Will TECX stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +129.2% from the last close, and Ticker Nerd's factor model ranks Tectonic Therapeutic, Inc. 52 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TECX stock forecast for 2030?

No analyst covering Tectonic Therapeutic, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TECX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $60 to $93 over the next 12 months.

What does Tectonic Therapeutic, Inc. do?

Tectonic Therapeutic Inc. is a biopharmaceutical company focused on the discovery and development of transformative therapies.

What is the latest news on TECX?

The most recent item we track (GlobeNewsWire, 6 Aug 2026): "Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights". Tectonic Therapeutic reported second-quarter 2026 financial results and business highlights, including completion of enrollment in the TX45 APEX Phase 2 trial in PH-HFpEF with topline results expected in early Q1 2027, an IDMC recommendation to continue that study without modification, and completion of dosing for six healthy volunteer cohorts in the TX2100 Phase 1a trial with topline results anticipated by end of Q3 2026. The company reported cash and equivalents of $227.1 million as of June 30, 2026, expected to fund operations into Q1 2029.

Company

About Tectonic Therapeutic, Inc.

Tectonic Therapeutic Inc. is a biopharmaceutical company focused on the discovery and development of transformative therapies. The primary aim of Tectonic Therapeutic is to create innovative treatments that target unmet medical needs, particularly in the realm of complex diseases. The company utilizes advanced technology platforms to identify and develop novel drugs, emphasizing precision medicine. This approach allows for the creation of tailored therapies that improve efficacy while minimizing side effects. Tectonic Therapeutic is highly influential in the biotechnology and healthcare sectors, where it collaborates with research institutions and industry partners to accelerate the development of its therapeutic programs. By focusing on cutting-edge research and leveraging proprietary techniques, the company plays a crucial role in advancing the landscape of medical treatment, contributing to improved patient outcomes and offering new hope for conditions previously deemed untreatable. In the financial markets, Tectonic Therapeutic is recognized for its potential to significantly impact the health and biotech industries, driven by its commitment to innovation and science-driven solutions. Its activities are closely watched by stakeholders and investors interested in the evolving field of medical biotechnology.

CEO Dr. Alise S. Reicin M.D., Ph.D. · 60 employees · United States · https://tectonictx.com